Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
Guido Finazzi(Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini"), Tiziano Barbui(University of Bergamo), Irene Bertozzi(University of Padua), Alessandra Carobbio(Ospedale Papa Giovanni XXIII), Ayalew Tefferi(Mayo Clinic), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Maria Luigia Randi(University of Padua), Heinz Gisslinger(Medical University of Vienna), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Elisa Rumi(University of Pavia), Elisabetta Antonioli(Azienda Ospedaliero-Universitaria Careggi), Marco Ruggeri(Ospedale San Bortolo), J. Thiele, Naseema Gangat(Mayo Clinic in Arizona), Francesco Rodeghiero(Ospedale San Bortolo), Francesco Passamonti(University of Milan)
Cited by 182
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k